Skip to main content
Caplight Logo









Artivila Biopharma

Artivila Biopharma

Private
ShenzhenHealthcare & Life Scienceshttps://artivila.com/

Last Round

Series A

Jun 25, 2026

Total Funding Raised

$35.7M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Artivila Biopharma is a biotechnology company that develops innovative drugs for autoimmune diseases, neurodegenerative diseases, and oncology using an AI-driven drug discovery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

drug discoveryAIDDsmall molecule therapeuticsautoimmune diseasebiotechCADDclinical-stage biopharmaAI drug discoverydrug developmenttherapeutic pipelinein silico drug designclinical trialsbiotech startupdrug licensingcomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Artivila Biopharma Comparables

Compare Artivila Biopharma with similar companies based on industry and business-model similarity.

Artivila Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MindRank
83%
Terray Therapeutics
79%
Genesis Molecular AI
79%

Artivila Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 25, 2026
VC RoundMar 31, 2022
SeedMar 30, 2021
AngelNov 1, 2019

Artivila Biopharma Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 25, 2026

    $13M round led by Green Pine Capital Partners

  • Sep 22, 2025

    Successful completion of Phase I study for ARD-885, a novel small molecule drug.

Artivila Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Artivila Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Artivila Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersShenzhen
Employee Range5
Year Founded2018
Last FundingJun 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?